Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Summit Therapeutics Q3 Adj. EPS $(0.13), Inline

Author: Benzinga Newsdesk | October 20, 2025 05:52am
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 160 percent decrease over losses of $(0.05) per share from the same period last year.

Posted In: SMMT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist